Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.
How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.
New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.
Knownwell's $20 million Series A funding round was led by A16Z and included participation from Flare Capital Partners. The company also launched an adolescent metabolic health program.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
In a new partnership, patients in need of weight loss support can receive primary care, mental health and chronic condition management through Hello Alpha. In between Hello Alpha visits, patients can access health coaching services from TrestleTree.
WeightWatchers' new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7.
Twin Health raked in $50 million in Series D financing. The startup seeks to help patients improve their metabolic health and reduce the need for medications through the “digital twin” technology it sells to employers and health plans.
Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Hims & Hers unveiled a new weight loss program on Monday that includes access to medications, educational content and digital tracking tools.
A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.
Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.